NCT03030183 - Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2017

Primary Completion Date

March 28, 2018

Study Completion Date

March 28, 2018

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG

Zilucoplan (RA101495)

0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC

Trial Locations (6)

Investigative Site, Manhasset

Investigative Site, Durham

Investigative Site, Chicago

Investigative Site, Dallas

Investigative Site, Los Angeles

Investigative Site, Duarte